Guardian Pharmacy Services Raises Full-Year EBITDA Guidance After Strong Q1 Performance
GRDN sits 91% above its 52-week low of $19.17.
Summary
Guardian Pharmacy Services reported strong first-quarter 2026 financial results, with net income increasing to $13.5 million from $9.3 million year-over-year and Adjusted EBITDA rising to $29.8 million from $23.4 million. The company also raised its full-year 2026 Adjusted EBITDA guidance to $123 million - $127 million, up from the previous $120 million - $124 million, citing discrete benefits and favorable payor dynamics. This positive update follows the company's significant financial improvement in fiscal year 2025, as noted in its recent 10-K. The raised guidance, driven by robust Q1 performance and effective navigation of the Inflation Reduction Act's impact, signals continued operational strength and could positively influence investor sentiment and stock valuation. Investors will watch for sustained growth in residents served and further updates on the impact of the IRA.
At the time of this announcement, GRDN was trading at $36.58 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $19.17 to $41.36. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.